SYNGENE — Syngene International Share News
0.000.00%
Last trade - 00:00- IN₹167.75bn
- IN₹160.76bn
- IN₹37.39bn
Brief: India's Biocon To Sell 10% Stake In Syngene On Feb 1, 2023 - CNBC-TV18 Citing Sources
Brief: India's Syngene International Says On Track To Achieve Guidance Including Upgraded Revenue Growth Target Announced In July
Brief: India's Syngene International Sept-Quarter Consol Profit Rises
Brief: India's Syngene International Sees High Teen Growth In FY23 Revenue From Operations
Brief: India's Syngene International June-Quarter Profit Falls
India's Syngene International hits 10-week high on Zoetis manufacturing deal
Brief: Syngene Signs 10-Yr Biologics Manufacturing Agreement With Zoetis
Brief: Syngene International To Buy Up To 26% Stake In Ampyr Renewable Energy Resources Eleven
Brief: Syngene International Consol March-Qtr Profit Falls
India's Gland Pharma, Laurus Labs gain as Jefferies initiates with 'buy'
Brief: Dyadic Announces Development Of Covid-19 Vaccine In India
Syngene targets delivering 500,000 vials of remdesivir in India as COVID-19 surges (updated)
Syngene targets delivering 500,000 vials of remdesivir in India in May - executive
Brief: Syngene And Deerfield Discovery And Development Sign 5-Year Strategic Collaboration
Zydus Cadila launches India's cheapest remdesivir version at $37 per vial
India's Cipla prices its generic remdesivir at $53.34 per vial, below rivals (updated)
India's Cipla set to undercut rivals with generic remdesivir -sources
Mylan prices its generic remdesivir in India at $64 per 100 mg vial (updated)
Mylan to launch generic remdesivir version in India at $64 per 100 mg vial